MA39915B1 - Composés de pladiénolide pyridine et leurs procédés d'utilisation - Google Patents
Composés de pladiénolide pyridine et leurs procédés d'utilisationInfo
- Publication number
- MA39915B1 MA39915B1 MA39915A MA39915A MA39915B1 MA 39915 B1 MA39915 B1 MA 39915B1 MA 39915 A MA39915 A MA 39915A MA 39915 A MA39915 A MA 39915A MA 39915 B1 MA39915 B1 MA 39915B1
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- pyridine compounds
- pladienolide pyridine
- pladienolide
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Diaphragms For Electromechanical Transducers (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461993423P | 2014-05-15 | 2014-05-15 | |
| PCT/US2015/030464 WO2015175594A1 (en) | 2014-05-15 | 2015-05-13 | Pladienolide pyridine compounds and methods of use |
| EP15727125.5A EP3143016B1 (en) | 2014-05-15 | 2015-05-13 | Pladienolide pyridine compounds and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA39915A MA39915A (fr) | 2017-03-22 |
| MA39915B1 true MA39915B1 (fr) | 2019-05-31 |
Family
ID=53284528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA39915A MA39915B1 (fr) | 2014-05-15 | 2015-05-13 | Composés de pladiénolide pyridine et leurs procédés d'utilisation |
Country Status (36)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3344780B1 (en) | 2015-09-01 | 2021-06-23 | Eisai R&D Management Co., Ltd. | Splice variants associated with neomorphic sf3b1 mutants |
| IL259198B2 (en) * | 2015-11-18 | 2023-04-01 | Eisai R&D Man Co Ltd | A solid form of paladinolide pyridine compound and methods of its use |
| JP2020514348A (ja) * | 2017-03-15 | 2020-05-21 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | スプライセオソーム変異及びその使用 |
| CN111727059A (zh) | 2017-10-31 | 2020-09-29 | 卫材研究发展管理有限公司 | 包含至少一种剪接体调控剂和至少一种选自BCL2抑制剂、BCL2/BCLxL抑制剂和BCLxL抑制剂的抑制剂的组合及其使用方法 |
| CA3096400A1 (en) * | 2018-04-09 | 2019-10-17 | Eisai R&D Management Co., Ltd. | Certain pladienolide compounds and methods of use |
| CA3096424A1 (en) * | 2018-04-12 | 2019-10-17 | Eisai R&D Management Co., Ltd. | Pladienolide derivatives as spliceosome targeting agents for treating cancer |
| IL278740B2 (en) * | 2018-06-01 | 2024-01-01 | Eisai R&D Man Co Ltd | Methods for using splicing modulators |
| CN119405833A (zh) | 2018-06-01 | 2025-02-11 | 卫材R&D管理有限公司 | 剪接调节抗体-药物缀合物及其使用方法 |
| IL262658A (en) * | 2018-10-28 | 2020-04-30 | Memorial Sloan Kettering Cancer Center | Prevention of age related clonal hematopoiesis and diseases associated therewith |
| EP4161966A1 (en) * | 2020-06-05 | 2023-04-12 | Eisai R&D Management Co., Ltd. | Anti-bcma antibody-drug conjugates and methods of use |
| US20240043928A1 (en) | 2020-11-04 | 2024-02-08 | Eisai R&D Management Co., Ltd. | Biomarkers for myelodysplastic syndrome (mds) and methods of using the same |
| EP4361136A4 (en) * | 2021-06-18 | 2025-08-13 | Univ Cordoba | Compound for the treatment of glioblastoma |
| CN113876771B (zh) * | 2021-11-12 | 2022-09-23 | 中国医学科学院基础医学研究所 | 一种靶向pabpc1的小分子药物及其在慢性髓系白血病中的应用 |
| WO2023131866A1 (en) | 2022-01-05 | 2023-07-13 | Eisai R&D Management Co., Ltd. | Biomarkers for myelodysplastic syndrome (mds) and methods of using the same |
| MA71743A (fr) | 2022-11-07 | 2025-05-30 | Eisai R&D Management Co., Ltd. | Procédé de production d'un composé macrolide |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI312681B (en) * | 2001-02-01 | 2009-08-01 | Novel physiologically active substance | |
| TWI334866B (en) | 2002-05-29 | 2010-12-21 | Mercian Corp | Novel physiologically active substances |
| RU2338741C2 (ru) | 2002-07-31 | 2008-11-20 | Мершан Корпорейшн | Новые физиологически активные вещества |
| US7576204B2 (en) | 2002-07-31 | 2009-08-18 | Mercian Corporation | Heterocyclic macrolide pharmaceutical agent, a method of producing the same and use of the same |
| AU2003285012A1 (en) | 2002-10-24 | 2004-05-13 | Sepracor, Inc. | Compositions comprising zopiclone derivatives and methods of making and using the same |
| RU2330069C2 (ru) | 2002-11-29 | 2008-07-27 | Мершан Корпорейшн | Способ получения макролидного соединения и штаммы streptomyces sp., mortierella sp. и micromonosporaceae |
| CN1886505A (zh) | 2003-11-27 | 2006-12-27 | 美露香株式会社 | 参与大环内酯类化合物的羟化作用的dna |
| CA2552553C (en) | 2003-11-28 | 2015-01-06 | Kanagawa Academy Of Science And Technology | Method of detecting liver cancer, diagnostic for liver cancer and remedy for cancer |
| JPWO2006003706A1 (ja) | 2004-07-02 | 2008-04-17 | 株式会社プラスワンテクノ | 組み合わせ計量技術 |
| CN1977046A (zh) | 2004-07-20 | 2007-06-06 | 卫材R&D管理有限公司 | 编码参与普拉地内酯生物合成的多肽的dna |
| TW200716744A (en) * | 2005-05-26 | 2007-05-01 | Eisai R&D Man Co Ltd | Genetically modified microorganism and process for production of macrolide compound using the microorganism |
| CN101282967B (zh) | 2005-10-13 | 2011-01-26 | 卫材R&D管理有限公司 | 普拉二烯内酯b和普拉二烯内酯d的全合成 |
| WO2008111464A1 (ja) * | 2007-03-05 | 2008-09-18 | Eisai R & D Management Co., Ltd. | スプライシング異常を指標とする抗ガン剤の作用検定方法 |
| US20080312317A1 (en) | 2007-04-12 | 2008-12-18 | Eisai R&D Management Co., Ltd. | 12 membered-ring macrolactam derivatives |
-
2015
- 2015-05-13 RS RS20190233A patent/RS58400B1/sr unknown
- 2015-05-13 WO PCT/US2015/030464 patent/WO2015175594A1/en not_active Ceased
- 2015-05-13 MA MA39915A patent/MA39915B1/fr unknown
- 2015-05-13 TW TW104115293A patent/TWI634115B/zh active
- 2015-05-13 SI SI201530641T patent/SI3143016T1/sl unknown
- 2015-05-13 SM SM20190158T patent/SMT201900158T1/it unknown
- 2015-05-13 EP EP15727125.5A patent/EP3143016B1/en active Active
- 2015-05-13 MY MYPI2016001944A patent/MY195081A/en unknown
- 2015-05-13 KR KR1020167016648A patent/KR101710318B1/ko active Active
- 2015-05-13 BR BR112016026638-2A patent/BR112016026638B1/pt active IP Right Grant
- 2015-05-13 JP JP2016526218A patent/JP6067943B1/ja active Active
- 2015-05-13 PE PE2016002233A patent/PE20170384A1/es unknown
- 2015-05-13 PH PH1/2016/502249A patent/PH12016502249B1/en unknown
- 2015-05-13 RU RU2016148887A patent/RU2707730C2/ru active
- 2015-05-13 DK DK15727125.5T patent/DK3143016T3/en active
- 2015-05-13 ES ES15727125T patent/ES2712401T3/es active Active
- 2015-05-13 TR TR2019/02328T patent/TR201902328T4/tr unknown
- 2015-05-13 ME MEP-2019-81A patent/ME03417B/me unknown
- 2015-05-13 LT LTEP15727125.5T patent/LT3143016T/lt unknown
- 2015-05-13 JO JOP/2015/0113A patent/JO3668B1/ar active
- 2015-05-13 UA UAA201612731A patent/UA119458C2/uk unknown
- 2015-05-13 AU AU2015259237A patent/AU2015259237B2/en active Active
- 2015-05-13 KR KR1020177004442A patent/KR102146726B1/ko active Active
- 2015-05-13 SG SG11201609693XA patent/SG11201609693XA/en unknown
- 2015-05-13 MX MX2016014997A patent/MX373324B/es active IP Right Grant
- 2015-05-13 HU HUE15727125A patent/HUE041838T2/hu unknown
- 2015-05-13 CN CN201580025344.0A patent/CN107074827B/zh active Active
- 2015-05-13 US US14/710,687 patent/US9481669B2/en active Active
- 2015-05-13 PL PL15727125T patent/PL3143016T3/pl unknown
- 2015-05-13 PT PT15727125T patent/PT3143016T/pt unknown
- 2015-05-13 HR HRP20190432TT patent/HRP20190432T1/hr unknown
- 2015-05-13 CA CA2947754A patent/CA2947754C/en active Active
- 2015-05-13 MX MX2020004476A patent/MX388580B/es unknown
- 2015-05-13 AR ARP150101485A patent/AR100431A1/es active IP Right Grant
- 2015-05-13 EP EP18210019.8A patent/EP3514154B1/en active Active
-
2016
- 2016-10-25 ZA ZA2016/07354A patent/ZA201607354B/en unknown
- 2016-10-26 IL IL24852916A patent/IL248529B/en active IP Right Grant
- 2016-11-08 CL CL2016002835A patent/CL2016002835A1/es unknown
-
2019
- 2019-02-22 CY CY20191100228T patent/CY1121550T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3504213A4 (en) | AMINO-PYRROLOPYRIMIDINONE COMPOUNDS AND METHOD FOR USE THEREOF | |
| EP3429635A4 (en) | ANTI-CRISPR COMPOUNDS AND METHOD OF USE | |
| EP3359168A4 (en) | THERAPEUTIC COMPOUNDS AND METHOD | |
| EP3380101A4 (en) | EIF4-A-INHIBITING COMPOUNDS AND METHODS THEREFOR | |
| EP3436048A4 (en) | NEOANTIGENE AND METHOD FOR THEIR USE | |
| MA43284A (fr) | Composés et leurs méthodes d'utilisation | |
| EP3436030A4 (en) | CHIMERIC RECEPTORS AND METHOD FOR USE THEREOF | |
| ME03417B (me) | Jedinjenje pladienolid piridina i postupci primjene | |
| EP2968440A4 (en) | CYTOTOXIC AND ANTIMITOTIC COMPOUNDS AND METHOD FOR USE THEREOF | |
| EP3319610A4 (en) | OXYSTEROLS AND METHOD OF USE THEREOF | |
| EP3319612A4 (en) | OXYSTEROLS AND METHOD OF USE THEREOF | |
| EP3307762A4 (en) | REPORTER CAS9 VARIANTS AND METHOD FOR USE THEREOF | |
| EP3390624A4 (en) | Modified site-directed modifying polypeptides and methods of use thereof | |
| EP3298168A4 (en) | STABILIZED REDUCING AGENTS AND METHOD FOR THEIR USE | |
| EP3377612A4 (en) | FUNCTIONAL EXPRESSION OF MONOOXYGENASES AND METHODS OF USE | |
| EP3307844A4 (en) | DRILLING LIQUIDS AND METHOD OF USE | |
| MA54252A (fr) | Composés de benzoxazépine oxazolidinone et leurs procédés d'utilisation | |
| MA55097A (fr) | Oxystérols et leurs procédés d'utilisation | |
| MA40921A (fr) | Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation | |
| MA47849A (fr) | Anticorps anti-gitr et leurs procédés d'utilisation | |
| EP3394065A4 (en) | TETRAHYDROPYRANYL-AMINO-PYRROLOPYRIMIDINONE AND METHOD OF USE THEREOF | |
| EP3303435A4 (en) | HYDROFLUOROLEFINES AND METHOD OF USE THEREOF | |
| EP3341027A4 (en) | TRANSFECTION COMPLEXES AND METHOD FOR USE THEREOF | |
| EP3341017A4 (en) | IMMUNOMODULATING COMPOSITIONS AND METHOD FOR USE THEREOF | |
| EP3303436A4 (en) | HYDROFLUOROLEFINES AND METHOD OF USE THEREOF |